Biting Dust
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
2010 Commonwealth Games ~ 2010 Nobel Prizes ~ Sachin Tendulkar ~ Rajasthan Royals ~ Kings XI Punjab ~ Sushil Kumar ~ Deepika Kumari ~ Somdev Devvarman ~ HR Bhardwaj
Home / India News / 2007 / January / January 17, 2007
Biting the Dust - Is Lipicard's Niastin® Next After Pfizer's Torcetrapib?

Top News

144 Section in Hyderabad ahead of Ayodhya verdict

Manmohan Singh to campaign in Bihar today

FBI failed to act on Headley's wife's terror link expose 3 yrs before Mumbai attacks

Craven's horror flicks 'were inspired by real stories'

RBI will intervene if inflows turn lumpy: Subbarao

Enforcement Directorate issues 'Look Out Circular' against Lalit Modi

Now, laser technology that destroys tumours using heat

Waist size, not BMI can foretell cardiovascular risk in children

Biting the Dust - Is Lipicard's Niastin® Next After Pfizer's Torcetrapib?

Hyderabad, Andhra Pradesh, India

With dramatic discontinuation of Torcetrapib development by Pfizer, questions are raised about other new therapies targeting HDL increase including Lipicard's Niastin - combination of novel NCE's for integrated Cholesterol Management.

Niastin® is the latest drug being developed for Integrated Cholesterol Management through Lipicard's novel platform technology for producing high therapeutic index drugs - drugs that are safer and more efficacious.

Prasad Sambaru CEO of Lipicard talking on the dramatic events of Torcetrapib said that it is very unfortunate that Pfizer has to end the development of Torcetrapib after incurring such huge costs. He lauded the way Pfizer has handled the Torcetrapib situation. He also added that developments at Pfizer will not have any effect on Niastin developments as the mechanism of action of Niastin and Torcetrapib are totally different, in fact, Niastin program has been put on fast track after the withdrawal of Torcetrapib by Pfizer.

The lipid management and control is effected through a two pronged attack -first reducing LDL and total cholesterol using Statins, and the other is to increase the HDL Cholesterol using Niacin etc. Both Statins and Niacin also increase the HDL and reduce the LDL, VLDL respectively, but predominantly Statins decrease LDL and Niacin increases HDL.

Niastin® is combination of novel NCE's for increasing the HDL as well as reducing the LDL and VLDL lipoproteins. When compared to Niacin and Statin combination drugs in the market, Niastin is expected to be more efficacious with less toxic side effects including muscle and liver toxicity and flushing. Niastin® is being produced using the same novel platform technology that produced the other high therapeutic drugs - Platrol® (Safe Antiplatelet drug), KeraKlear® (Safe and clear solution for Keratoconjuctivities), etc.

About Lipicard Technologies:

Lipicard Technologies Limited develops innovative and novel High Therapeutic Index Drugs for Lipid management and cardio protection in collaboration with Life Enhancing Technologies LLC. USA. PLATROL® is the first safe antiplatelet drug being developed for cardio-protection. Next in line are the integrated Lipid management drug Niastin for increasing HDL and lowering LDL, and safe NSAIDs.

PLATROL® is registered trademarks of Life Enhancing Technologies.

Prasad Sambaru, Lipicard Technologies Limited, +91 (040) 2354 0413/ 2354 1068

Source: Lipicard Technologies Limited (Business Wire India)

Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.

India News / Press Releases on January 17, 2007

Outsource Partners International Achieves SAS 70 Type II Audit
Business Wire India

CREDAI to Organise its 'Second National Exhibition of Developers and Housing Finance Institutions' at New Delhi
Business Wire India

Increasing Complexity of Electronic Products Drives Innovations in the Power Management IC Domain
Business Wire India

The SMT Software Market Poised To Capitalize On Potential Opportunities
Business Wire India

Biting the Dust - Is Lipicard's Niastin® Next After Pfizer's Torcetrapib?
Business Wire India

NIIT Technologies Ltd. Q3 Consolidated Quarter Results- Profit After Tax up 92 % YoY, at Rs. 34.6 crore
Business Wire India

Kingfisher Airlines Launches Direct Flights Between Bangalore and Thiruvananthapuram
Business Wire India

Sify to Report Third Quarter 2006 Fiscal Year Financial Results on Monday, January 22, 2007
Business Wire India

eTaxBay Announces US Tax Management Portal for NRIs
Business Wire India

Also see International News / Press Releases on January 17, 2007

Suggested pages for your additional reading on Facebook

© 2000-2017 All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us